Breakthrough Pancreatic Cancer Drug Doubles Survival Time

In a development that could transform the landscape of cancer treatment, Revolution Medicines has announced stunning results from its Phase 3 RASolute 302 clinical trial of daraxonrasib—a drug that targets the previously "undruggable" KRAS mutation in pancreatic cancer. The drug demonstrated unprecedented overall survival benefits, effectively doubling survival time for patients with metastatic pancreatic cancer.

Pancreatic cancer has long been one of oncology's most formidable challenges. With a five-year survival rate of just 12%, it has been resistant to most treatment advances that have improved outcomes for other cancers. The KRAS mutation is present in approximately 95% of pancreatic cancers and had been considered impossible to target with drugs—until now.

The success of daraxonrasib validates a new approach to targeting genetic mutations previously thought inaccessible to pharmaceutical intervention. Beyond the immediate impact on pancreatic cancer patients, this breakthrough opens the door to treating other KRAS-driven cancers, including certain lung and colorectal cancers.

Key Facts

• Daraxonrasib doubled survival time in metastatic pancreatic cancer patients
• KRAS mutations present in ~95% of pancreatic cancers
• Pancreatic cancer five-year survival rate: approximately 12%
• Phase 3 RASolute 302 trial results announced April 2026
• Source: Revolution Medicines press release, STAT News analysis

Why This Matters

The pharmaceutical industry has spent decades attempting to drug the KRAS protein, with countless failures along the way. The protein's smooth, featureless surface made it appear impossible to bind with small molecules. Daraxonrasib represents a new class of compounds that can latch onto a specific KRAS mutation (G12C), effectively switching off the cancer-driving signal.

This success follows years of incremental progress in understanding the protein's structure and behavior. It exemplifies how persistence in basic research can eventually yield transformative clinical applications.

What We Don't Know Yet

While these results are genuinely exciting, important limitations exist. The drug targets only one specific KRAS mutation (G12C), which represents a subset of pancreatic cancers. Side effects and long-term safety data require continued monitoring. The drug's cost and accessibility remain unknown—breakthrough cancer therapies often carry price tags exceeding $100,000 annually, raising questions about equitable access.

Category: Health & Medicine
Published: April 22, 2026